| Literature DB >> 28846069 |
Ioannis Mitroulis1, Lan-Sun Chen1, Rashim Pal Singh1, Ioannis Kourtzelis1, Matina Economopoulou2, Tetsuhiro Kajikawa3, Maria Troullinaki1, Athanasios Ziogas1, Klara Ruppova1, Kavita Hosur3, Tomoki Maekawa3, Baomei Wang3, Pallavi Subramanian1, Torsten Tonn4, Panayotis Verginis1,5, Malte von Bonin6, Manja Wobus6, Martin Bornhäuser6,7, Tatyana Grinenko1, Marianna Di Scala8, Andres Hidalgo8,9, Ben Wielockx1,7, George Hajishengallis3, Triantafyllos Chavakis1,7.
Abstract
Hematopoietic stem cells (HSCs) remain mostly quiescent under steady-state conditions but switch to a proliferative state following hematopoietic stress, e.g., bone marrow (BM) injury, transplantation, or systemic infection and inflammation. The homeostatic balance between quiescence, self-renewal, and differentiation of HSCs is strongly dependent on their interactions with cells that constitute a specialized microanatomical environment in the BM known as the HSC niche. Here, we identified the secreted extracellular matrix protein Del-1 as a component and regulator of the HSC niche. Specifically, we found that Del-1 was expressed by several cellular components of the HSC niche, including arteriolar endothelial cells, CXCL12-abundant reticular (CAR) cells, and cells of the osteoblastic lineage. Del-1 promoted critical functions of the HSC niche, as it regulated long-term HSC (LT-HSC) proliferation and differentiation toward the myeloid lineage. Del-1 deficiency in mice resulted in reduced LT-HSC proliferation and infringed preferentially upon myelopoiesis under both steady-state and stressful conditions, such as hematopoietic cell transplantation and G-CSF- or inflammation-induced stress myelopoiesis. Del-1-induced HSC proliferation and myeloid lineage commitment were mediated by β3 integrin on hematopoietic progenitors. This hitherto unknown Del-1 function in the HSC niche represents a juxtacrine homeostatic adaptation of the hematopoietic system in stress myelopoiesis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28846069 PMCID: PMC5617665 DOI: 10.1172/JCI92571
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808